Summary
The in vivo dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) labelled with11 C in the Β position has been used for positron emission tomography studies of L-DOPA utilization in the brain. The brain uptake and kinetics of L-[11 C]DOPA-derived radioactivity were studied in healthy male volunteers, and the specific utilization, i.e. decarboxylation rate of L-[11 C]DOPA in different brain areas, was quantified using a brain region devoid of specific L-[11C]DOPA utilization as reference. Total uptake of L-[11 C]DOPA-derived radioactivity measured in the brain varied two- to threefold between subjects, with highest radioactivity in the striatal region. Specific utilization of L-[11C]DOPA radioactivity in the striatal region and in the prefrontal cortex varied twofold between subjects. No specific utilization was observed in other regions of the brain. The uptake of radioactivity in the brain increased dose-dependently with the simultaneous administration of unlabelled L-DOPA up to 10 mg. On the other hand, a decrease in brain radioactivity uptake was measured after pretreatment with 1 mg/kg oral L-DOPA, indicating competition for transport across the blood-brain barrier. Benserazide 0.5 mg/ kg orally increased somewhat the radioactivity uptake to the brain. None of these pharmacological perturbations demonstrated any clearcut effect on specific utilization of L-[11C]DOPA. Thus,11C-labelled L-DOPA is introduced as an alternative to the well-established L-6-[18 F]fluoro-DOPA methodology in clinical studies on brain L-DOPA uptake and dopamine synthesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bergström M, Litton J, Eriksson L, Bohm C, Blomquist G (1982) Determination of object contour from projections for attenuation in cranial positron emission tomography. J Comput Assist Tomogr 6: 365–372
Bjurling P, Antoni G, Watanabe Y, Långström B (1990a) Enzymatic synthesis of carboxy11C-labelled L-tyrosine, L-DOPA, L-tryptophan and 5-hydroxy-L-tryptophan. Acta Chem Scand 44: 178–182
Bjurling P, Watanabe Y, Oka S, Nagasawa T, Yamada H, Långström B (1990b) Multienzymatic synthesis of Β-11 C-labelled L-tyrosine and L-DOPA. Acta Chem Scand 44: 183–188
Chiueh CC, Cohen RM, Kirk KL, Finn RD, Firnau G, Kung HF (1987) Imaging of pre- and post-synaptic adaptations in the nigrostriatal dopaminergic system of MPTP-induced parkinsonism. In: Beart PM, Woodruff GN, Jackson DM (eds) Pharmacology and functional regulation of dopaminergic neurons. Macmillan Press, pp 329–335
Cumming P, Boyes BE, Martin WR, Adam M (1987) The metabolism of [18F]6-fluoro-L-3,4,-dihydroxyphenylalanine in the hooded rat. J Neurochem 48: 601–608
Firnau G, Sood S, Chirakal R, Nahimas C, Garnett ES (1987) Cerebral metabolism of 6-[18F]L-3,4-dihydroxphenylalanine in the primate. J Neurochem 48: 1077–1082
Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES (1988) Metabolites of 6-[18F]fluoro-L-DOPA in human blood. J Nucl Med 29: 363–369
Garnett ES, Firnau G, Chan PKH, Sood S, Belbeck LW (1978) [18 F]Fluoro-dopa, an analogue of dopa, and its use in external measurements of storage, degradation and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 75: 464–467
Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305: 137–138
Gjedde A (1982) Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res Rev 4: 237–274
Haaparanta M, SipilÄ H, Solin O (1988) Fast HPLC separation of [18 F]-fluorodopa isomers. Ann Turkuensis 27: 229–232
Holz P (1939) Dopa-dekarboxylase. Naturwissenschaften 27: 724–725
Horne MK, Cheng CH, Wooten GF (1984) The cerebral metabolism of L-dihydroxyphenylalanine. An autoradiographic and biochemical study. Pharmacology 28: 12–26
Korf J, Reiffers S, Beerling-van der Holen HD, Lakke JPWF, Paaus AMJ, Vaalburg W, Woldring MG (1978) Rapid decarboxylation of carbon-11 labelled DL-DOPA in the brain: a potential approach for external detection of nervous structures. Brain Res 145: 59–67
Leenders KL, Palmer A, Tuston D, Quinn N, Firnau F, Garnett S, Nahmias C, Jones T, Marsden CD (1986a) DOPA uptake and dopamine receptor binding visualized in the human brain in vivo. In: Fahn S, Marsden CD, Jenner P, Teychenne P (eds) Recent developments in Parkinson's disease. Raven Press, New York, pp 103–113
Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD (1986b) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853–860
Leenders KL, Poewe WH, Palmer A, Brenton DP, Frackowiak RSJ (1986c) Inhibition of L-[18 F]fluoro-DOPA uptake in the human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20: 258–262
Liskowsky DR, Potter LT (1985) A pre-positron emission tomography study of L-3,4-dihydroxy-[3 H]phenylalanine distribution in the rat. Neurosci Lett 53: 161–167
Litton J, Bergström M, Eriksson L, Bohm C, Blomquist G (1984) Performance study of the 384 positron camera system for emission tomography of the brain. J Comput Assist Tomogr 8: 74–87
Lloyd KG, Hornykiewicz O (1970) Parkinson's disease. Activity of L-DOPA decarboxylase in discrete brain areas. Science 170: 1212–1213
Lovenberg W, Weissenbach H, Udenfriend S (1962) Aromatic L-amino acid decarboxylase. J Biol Chem 237: 89–93
Martin WRW, Palmer MR, Patlak CS, Calne DB (1989) Nigrostriatal functions in humans studied with positron emission tomography. Ann Neurol 26: 535–546
Melamed E, Hefti F, Pettibone DJ, Liebman J, Wurtman RJ (1981) Aromatic L-amino acid decarboxylase in rat corpus striatum: implication for actions of L-dopa in parkinsonism. Neurology 31: 651–655
Melega WP, Luxen A, Permutter MM, Nissenson CHK, Phelps ME, Barrio JR (1990) Comparative in vivo metabolism of 6-[18 F]fluoro-L-DOPA and [3 H]L-DOPA in rats. Biochem Pharmacol 39: 1853–1860
Pate BD, Hewitt KA, Martin WR, Snow BJ, Calne DB (1990) In vivo studies of presynaptic dopaminergic function in non-human primates by PET-scanning. Neurology 40 [Suppl 1]: 264
Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3: 1–7
Tedroff J, Aquilonius S-M, Hartvig P, Bredberg E, Bjurling P, Långström B (1991a) Cerebral uptake and utilization of [Β-11 C]-L-DOPA in Parkinson's disease measured by positron emission tomography — relations to motor response. Acta Neurol Scand (in press)
Tedroff J, Aquilonius S-M, Hartvig P, Lundqvist H, Bjurling P, Långström B (1991b) Estimation of regional cerebral utilization of [11 C]-L-3,4-dihydroxyphenylalanine (DOPA) in the primate by positron emission tomography. Acta Neurol Scand (in press)
Author information
Authors and Affiliations
Additional information
A contribution from the Uppsala University PET Center.
Rights and permissions
About this article
Cite this article
Hartvig, P., ågren, H., Reibring, L. et al. Brain kinetics of L-[Β-11 C]DOPA in humans studied by positron emission tomography. J. Neural Transmission 86, 25–41 (1991). https://doi.org/10.1007/BF01250373
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01250373